Coherus BioSciences is a biotechnology business based in the US. Coherus BioSciences shares (CHRS) are listed on the NASDAQ and all prices are listed in US Dollars. Coherus BioSciences employs 249 staff and has a trailing 12-month revenue of around $301.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.51 |
|---|---|
| 52-week range | $1.25 - $5.47 |
| 50-day moving average | $1.74 |
| 200-day moving average | $2.26 |
| Wall St. target price | $10.29 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.74 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.51 from 2024-07-24
| 1 week (2024-07-19) | -7.93% |
|---|---|
| 1 month (2024-06-26) | -9.04% |
| 3 months (2024-04-26) | -25.98% |
| 6 months (2024-01-26) | -35.47% |
| 1 year (2023-07-26) | -66.67% |
|---|---|
| 2 years (2022-07-26) | -79.68% |
| 3 years (2021-07-26) | 12.85 |
| 5 years (2019-07-26) | 16.69 |
| Revenue TTM | $301.9 million |
|---|---|
| Gross profit TTM | $-58,399,000 |
| Return on assets TTM | -17.26% |
| Return on equity TTM | -1657.06% |
| Profit margin | -19.64% |
| Book value | $-0.72 |
| Market Capitalization | $188.2 million |
TTM: trailing 12 months
We're not expecting Coherus BioSciences to pay a dividend over the next 12 months.
Over the last 12 months, Coherus BioSciences's shares have ranged in value from as little as $1.25 up to $5.465. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Coherus BioSciences's is 0.6. This would suggest that Coherus BioSciences's shares are less volatile than average (for this exchange).
Coherus BioSciences, Inc. , a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.